Lunch Symposium 4

Objectives:

Norway was one of the first countries to implement widespread biosimilar use, led by pioneering research such as the NOR-SWITCH study. This session features Professor Tore K. Kvien, who will share his extensive, decade-long experience with biosimilars in clinical practice. The discussion will move beyond theoretical benefits to focus on long-term real-world data, the evolution of clinician and patient perspectives, and the practical “Experience” that has shaped current rheumatology standards. This is a unique opportunity to learn from the definitive history of biosimilar integration in Europe.